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SUMMARY
There is evidence that changes in branched-chain amino acid (BCAA)
levels may correlate with the efficacy of therapeutic interventions for
affecting improvement in metabolic control. The objective of this study
was to evaluate whether serum concentrations of BCAAs (leucine,
isoleucine, valine) could mediate in insulin sensitivity and glucose
tolerance after continuous positive airway pressure (CPAP) treatment in
patients with obstructive sleep apnea (OSA). A prospective randomized
controlled trial of OSA patients with morbid obesity was conducted.
Eighty patients were randomized into two groups: 38 received conser-
vative treatment and 42 received CPAP treatment for 12 weeks. Plasma
levels of BCAA, glucose tolerance and insulin resistance were evaluated
at baseline and after treatment. After treatment, significant decreases of
leucine levels were observed in both groups when compared with
baseline levels (P < 0.005). With respect to patients with normal glucose
tolerance (NGT), patients with impaired glucose tolerance (IGT) had
higher baseline levels of isoleucine (78  16 versus 70  13 lmol L1,
P = 0.014) and valine (286  36 versus 268  41 lmol L1, P =
0.049), respectively. Changes in levels of leucine and isoleucine after
treatment were related negatively to changes in fasting plasma glucose
and glycosylated haemoglobin values only in the conservative group
(P < 0.05). In summary, we found that the treatment with CPAP for
12 weeks caused similar changes in circulating BCAAs concentrations to
conservative treatment and a differential metabolic response of CPAP
and conservative treatment was observed between the relationship of
BCAAs and glucose homeostasis. Additional studies are needed to
determine the interplay between branched-chain amino acids and
glucose metabolism in patients with sleep apnea.
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INTRODUCTION
Despite increasing evidence that obstructive sleep apnea
(OSA) may impact upon metabolic syndrome or some of its
components, independently of obesity, the underlying mech-
anistic links between OSA and metabolic disturbances have
not been well delineated (Bonsignore and Eckel, 2009; Kent
et al., 2015).
Recent metabolic profiling of plasma amino acids has
revealed a consistent pattern, especially of branched-chain
amino acid (BCAA) profiles associated with multiple presen-
tations of metabolic diseases, including obesity and insulin
resistance (Cheng et al., 2012; Giesbertz and Daniel, 2016).
Dysregulation in BCAA metabolism has been detected in
obesity (Newgard, 2012; Shah et al., 2012), and recent
studies revealed significant positive associations between
circulating BCAAs (leucine, isoleucine, valine) and insulin
resistance. Moreover, the plasma concentrations of BCAAs
have been involved in the risk of developing type 2 diabetes
mellitus and are a prognostic factor of improvement in insulin
sensitivity after therapeutic interventions (Laferrere et al.,
2011; Magkos et al., 2016; Wang et al., 2011).
Studies addressing the effect of continuous positive airway
pressure treatment (CPAP) on glucose metabolism have
reported conflicting results (Coughlin et al., 2007; Harsch
et al., 2004; Pepin et al., 2012; Weinstock et al., 2012; West
et al., 2007). In a recent randomized controlled trial we
demonstrated that CPAP treatment in subjects with both
morbid obesity and severe sleep apnea improve glucose
tolerance without concomitant changes in the homeostasis
model assessment–insulin resistance (HOMA-IR) index
(Salord et al., 2016). As the HOMA-IR index largely reflects
hepatic insulin resistance, these results suggest a potential
role of CPAP treatment in peripheral insulin resistance.
In this context, we hypothesized that changes in BCAA
metabolism could mediate in the improvement in insulin
sensitivity and glucose tolerance after CPAP treatment. To
test this hypothesis, we have measured a profile of amino
acids to gain an understanding of the differential metabolic
response to 12 weeks of CPAP treatment compared to
conservative (CT) in a population with morbid obesity and
severe OSA without clinically overt diabetes.
METHODS
This is an ancillary study of a prospective, randomized
controlled trial (RCT) designed to address whether continu-
ous positive airway pressure treatment improved glucose
metabolism in severe OSA patients with morbid obesity
without diabetes. The study protocol and study flowchart has
been reported previously (Salord et al., 2016).
Trial design
A parallel RCT comparing 12 weeks of CPAP treatment to
CT was designed.
Participants and study settings
Patients included in the obesity surgery programme were
studied prospectively in two referral sleep clinics in Barcelona
from January 2009 to July 2011. Inclusion criteria for the
obesity surgery programme were: age between 18 and
65 years; a body mass index (BMI) ≥40 kg m2 or BMI
≥35 kg m2 with comorbidity related to obesity (hyperten-
sion, heart disease, degenerative osteoarthritis and respira-
tory complications). Eligible patients with apnea hypopnea
index (AHI) >30 episodes h1 after a full overnight
polysomnography were randomized to receive individualized
lifestyle counselling therapy plus CPAP (CPAP group) or
conservative treatment (CT group). The exclusion criteria
were: current or previous CPAP treatment, previously known
diabetes mellitus or diabetic treatment, unstable cardiovas-
cular conditions, severe cognitive or psychiatric disorders,
chronic obstructive pulmonary disease, pregnancy, past or
current history of alcohol abuse, refusal to participate,
disabling daytime sleepiness, professional drivers or profes-
sionals performing potentially dangerous activities.
Interventions and protocol
Included patients were randomized to receive individualized
lifestyle counselling therapy plus CPAP (CPAP group) or
conservative treatment (CT group) consisting only of individ-
ualized lifestyle counselling therapy. At baseline and after
12 weeks, each participant completed a detailed question-
naire on medical history, cardiovascular risk factors and
current medication. Exercise level and sleep duration were
recorded in a self-administered International Physical Activity
Questionnaire (IPAQ) and a sleep diary for 15 consecutive
days.
In order to aim for a weight loss of 10% of initial weight, the
calorie goals during the preparation for bariatric surgery were
1200 kcal day1 for women and 1500 kcal day1 for men.
These goals were reduced to 1000–1200 kcal day1,
respectively, if participants did not lose weight satisfactorily.
The composition of the diet was structured to enhance
glycaemic control and to minimize cardiovascular risk factors.
The recommended diet was based on the guidelines of the
American Dietitians Association (Raynor and Champagne,
2016) and included a maximum of 30% of total calories from
total fat, a maximum of 10% of total calories from saturated
fat and a minimum of 15% of total calories from protein.
Patients were recommended to increase their intake of fruits,
vegetables, poultry, fish and lean meat and limiting dairy fats,
fatty meat, sweets, pastries and desserts. The physical
activity prescription was 175 min per week of moderate or
intensity activity, such as mild or brisk walking, depending on
the patient’s condition.
The nutritionist provided face-to-face counselling individu-
ally four times during the waiting-list period, and at each
individual visit patients were asked to bring a 3-day food diary
and were asked about the lifestyle changes he or she had
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made. Compliance with the diet and exercise was monitored
by these individual interviews by the nutritionist.
Excessive daytime sleepiness was quantified by the
Epworth Sleepiness Scale. Anthropometric characteristics
included BMI, neck circumference, waist circumference,
waist/hip ratio and percentage of body fat mass measured
by electrical bioimpedance (BIA 101; Akern Bioresearch,
Florence, Italy). Clinical blood pressure (BP) was measured
according to Spanish guidelines.
Ethical issues
After the indication for bariatric surgery, patients generally
spend more than 1 year on the waiting-list for surgery. During
this time, patients receive medical care from an endocrinol-
ogist and respiratory and sleep studies are performed in
order to reduce the peri-operative complications associated
with untreated sleep apnea. For ethical reasons, patients
were included into our study after the first evaluation by the
endocrinologist, and were prioritized for overnight
polysomnography (PSG) in order to avoid a delay at the
beginning of treatment. At the end of the 12-week study
period, CPAP treatment was initiated in all CT patients.
The studyprotocolwasapprovedbybothEthical Committees:
Comite Etico de Investigacion Clınica de La Fundacio deGestio
Sanitaria del Hospital de la Santa Creu i Sant Pau de Barcelona
and Comite Etico de Investigacion Clınica del Hospital Univer-
sitari de Bellvitge (PR052/08, 07/064/797). All participants gave
their informedwrittenconsent.The trial registrationnumber in the
ClinicalTrials.gov was NCT 01029561.
Definitions
At baseline and after 12 weeks of CPAP or CT, a venous
blood sample was obtained from all patients in fasting
conditions.
Glycosylated haemoglobin (HbA1c), insulin and fasting
plasma glucose (FPG) were determined using standard
laboratory methods. In patients with FPG <6.7 mmol L1,
plasma glucose measurements were obtained 5 min before
and 2 h after administration of 75 g oral glucose (2-h PG).
Based on the results of the oral glucose tolerance test
(OGTT), normal glucose tolerance (NGT) was defined as 2-h
PG <7.8 mmol L1, impaired glucose tolerance (IGT) as 2-h
PG from 7.8 to 11.0 mmol L1 and diabetes as 2-h PG
≥11.1 mmol L1. Insulin resistance was estimated using the
HOMA-IR (Matthews et al., 1985).
Metabolic syndrome (MetS) was defined in accordance
with the National Cholesterol Education Program Adult
Treatment Panel III (NCEP-ATPIII) modified criteria (Alberti
et al., 2009).
OSA was determined by a full overnight PSG. CPAP
titration was performed by an overnight PSG with manual
CPAP titration or by autotitration devices. Objective treatment
compliance was determined by dividing the number of hours
recorded by the CPAP device’s built-in hour meter by all
nights during the study period. Patients with an average use
time <4 h per night were considered non-compliant.
Amino acid measurements
Analysis of serumsampleswas conducted in theBiochrom30+
chromatographicanalyser (Biochrom,Cambridge,UK). Inbrief,
samplesweredeproteinizedandaminoacidswereanalysedby
high-performance liquid chromatography and spectrometric
detection. The analytical coefficient of variation for each amino
acid was: leucine 9.0%, isoleucine 7.0% and valine 6.5%.
Sample size, randomization and statistical analysis
Sample size calculations showed that 42 subjects were
needed in each group to detect a difference greater than or
equal to 1 unit of HOMA-IR, assuming a standard deviation of
1.5 based on previous results in the clinical database ofmorbid
obesity in one of our centres, with a minimum power of 80%.
The dropout rate for the study was estimated at 15%. Simple
randomization was performed by a statistician not involved in
the study using a computer-generated sequence of random
numbers for balanced allocation. Math.random function was
used to generate the random allocation sequence prior to
study activation. We did not use any restriction or blocking
method. Randomization was assigned using the central
database, where the previously reported number generation
algorithm was stored. According to eligibility screening by the
research co-ordinator, the system generated a unique number
that could not be modified or erased.
The treatment arm was not blinded to the participants, care
providers or the person assessing the statistical analysis.
Two hundred forty-three patients were assessed initially for
the study. Fig. 1 shows exclusion causes and follow-up of
participants. Ninety-eight patients were recruited, 44 of whom
were assigned to CT and 54 to CPAP. Twelve patients in the
CPAP group and six in the CT group discontinued follow-up;
therefore, 80 patients completed the study and were analysed.
Continuous variables were shown as mean  standard
deviation for normally distributed data or median (and
interquartile range) for non-normally distributed data, and
categorical variables as proportions. The intention-to-treat
principle was applied for the analysis of the differences
between treatment groups, but missing data were not
imputed in order to avoid the dilution effect.
Changes from baseline of treatment with CPAP and
conservative treatment were calculated by subtracting the
values after the 12-week intervention period from the values
before the period; the t-test or the Mann–Whitney U-test were
used. The chi-square test or Fisher’s exact test were used for
categorical variables. We aggregated patients with IGT and
those who screened positive for diabetes in the IGT category,
as only three patients proved to be diabetic in the OGTT.
Changes after 12 weeks in IGT and MetS were categorized
as improved, worsened or unchanged. Spearman’s rank
correlation was performed for correlating demographic and
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sleep data and BCAA concentrations. To determine the
possible effect of CPAP on BCAA levels, we performed a
multivariate analysis with study group, age, gender, BMI,
baseline glucose, HOMA-IR, HBA1c and BCAA levels as the
independent variables and post-treatment BCAA levels as
the dependent variables.
Two-sided P-values of less than 0.05 were considered to
indicate statistical significance. Statistical analysis was per-
formed with the statistical software package SPSS version 19
(IBM Corp., Armonk, NY, USA).
RESULTS
Table 1 shows the baseline characteristics of the CPAP and
CT groups. Patients in the CT group had higher BMI and
waist circumference when compared to the CPAP group.
There were no major differences in age, sex, OSA severity,
glycaemic variables or prevalence of MetS between the two
groups.
Changes in BCAA levels after treatment
After 12 weeks of treatment, both groups presented a slight
but equivalent weight loss. Most variables explored, including
FPG, HOMA-IR and HbA1c, were unchanged in both groups.
Metabolic syndrome prevalence were not significantly differ-
ent between the CPAP and conservative intervention groups.
In the CPAP group, IGT reversed in 23.7% and glucose
tolerance remained unchanged in 76.3%. No patients wors-
ened in this group. In the CT group, IGT reverted to NGT in
14.7%, remained unchanged in 70.6% and 14.7% developed
IGT (P = 0.039 at Fisher’s exact test) (Salord et al., 2016).
Assessed for eligibility (n = 243)
Excluded  (n = 145)
♦ Not meeting inclusion criteria (n = 131)
♦ Declined to participate (n = 11)
♦ Other reasons (n = 3)
Analysed  (n = 40)
♦ Excluded from analysis (extremely obesity) 
(n = 2)
Lost to follow-up (abandon) (n = 9)
Discontinued intervention (n = 0)
Allocated to CPAP (n = 54)
♦ Received allocated intervention (n = 51)
♦ Did not receive allocated intervention 
(pregnancy and bariatric surgery) (n = 3)
Lost to follow-up (abandon) (n = 6)
Discontinued intervention (n = 0)
Allocated to conservative treatment (n = 44)
♦ Received allocated intervention (n = 44)
♦ Did not receive allocated intervention(n = 0)
Analysed  (n = 38)
♦ Excluded from analysis (n = 0)
Allocation
Analysis
Follow-up
Randomized (n = 98)
Enrollment
Figure 1. Study flowchart.
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The mean values of glucose variables and BCAAs
(leucine, isoleucine, valine) in the CPAP and the conserva-
tive groups are shown in Table 2.
Among plasma BCAAs, significant decreases of leucine
levels were observed in both groups when compared with the
baseline levels. Finally, because the CT group presented
higher levels of obesity than the CPAP group, the analysis
was repeated after excluding five patients with extreme
obesity. The BMI of the two groups became comparable
(45.7  5.1 and 47.5  5.1 kg m2). The decrease in
leucine levels remained significant in both groups. We found
no apparent modification of the initial results after adjusting
for age, gender, BMI, baseline glucose, HOMA and HbA1c
levels. Results also remained unchanged after excluding six
patients with <4 h of CPAP compliance.
Associations of BCAA levels at baseline
Table 3 shows the correlation coefficients of BCAA levels with
anthropometric, sleep and glycaemic variables at baseline of
both groups of patients included in the study. Isoleucine levels
were associated with HbA1c (r = 0.287, P = 0.011) and with
time spent with SpO2 <90% (r = 0.244, P = 0.032).
Relationships between baseline BCAAs and post-
treatment metabolic data
In the CT group, a positive correlation was detected between
isoleucine and leucine measured at baseline and FPG and
HbA1c values measured after treatment (FPG, isoleucine:
r = 0.463, P = 0.004; leucine: r = 0.387, P = 0.018; HbA1c,
isoleucine: r = 0.538,P = 0.001; leucine; r = 0.335,P = 0.049).
Changes in levels of leucine and isoleucine after treatment
were related negatively to changes in FPG and HbA1c values
only in the CT group (Table 4).
Relationship between BCAA and glucose tolerance
Compared to patients with NGT, patients with IGT had higher
levels of isoleucine (78  16 versus 70  13 lmol L1,
P = 0.014) and valine (286  36 versus 268  41 lmol L1,
P = 0.049), respectively (Fig. 2). In response to treatment,
changes of leucine, isoleucine and valine did not differ
between patients with IGT and patients with NGT. When this
analysis was performed only in patients in which IGT reverted
to NGT (nine in the CPAP group and five in the CT group), a
significant decrease was observed in leucine levels
(141  18 lmol L1 at baseline versus 122  24 lmol L1
after treatment, P = 0.012).
In patients with IGT, a positive correlation between
baseline BCAA levels and HbA1c values measured post-
treatment (isoleucine; r = 0.719, P = 0.045; leucine:
r = 0.755, P = 0.031; valine: r = 0.755, P = 0.031) was
observed in the CT group. No associations were detected
between these variables in the CPAP group.
DISCUSSION
In the present randomized controlled intervention study,
performed in non-diabetic subjects with morbid obesity and
Table 1 Clinical and biochemical characteristics of continuous positive airway pressure (CPAP) and conservative treatment groups at
baseline
CPAP group
n = 42
Conservative treatment group
n = 38 P-value
Age, years 48.5  8.6 44.6  9.4 0.057
Gender, males n (%) 11 (26) 11 (29) 0.783
BMI, kg m2 45.7  5 49.3  6.6 0.007
Waist circumference, cm 130 (120–137) 134 (126–147) 0.040
Epworth scale 7.9  4.5 7.9  5.2 0.892
Sleep efficiency, % 82.8 (74.0–87.7) 77.1 (69.3–86.0) 0.321
AHI, episodes h1 68.3 (43–88) 52.6 (37–78) 0.276
Time spent <90% of TST, % 13.8 (6–29) 17.7 (6–41) 0.765
ODI 3%, h1 57.8  28.0 52.5  28.0 0.402
Metabolic syndrome, n (%) 34 (81) 29 (76.3) 0.613
Fasting glucose, mmol L1 5.8  0.70 5.7  0.77 0.533
2 h-PG, mmol L1* 6.7 (5.3–8.9) 6.4 (5.0–7.0) 0.671
HbA1c, % 5.8  0.4 5.7  0.4 0.363
HOMA-IR* 6.8  3.3 6.4  3.6 0.628
Leucine (lmol L1) 136  20 140  25 0.563
Isoleucine (lmol L1) 74  12 75  16 0.644
Valine (lmol L1) 273  37 276  44 0.314
Data are presented as n (%) for categorical data or as mean  standard deviation or median (interquartile range) for continuous data; t-test or
Mann–Whitney U-test were used for continuous variables and v2 or Fisher’s exact test were used for categorical variables.
BMI, body mass index; AHI, apnea–hypopnea index; HbA1c, glycosylated haemoglobin; HOMA-IR, homeostasis model assessment–insulin
resistance; TST, total sleep time; ODI, oxygen desaturation index; time spent <90% of TST, time spent with SpO2 <90%.
*2 h-PG (n = 35, n = 34), HOMA-IR (n = 40, n = 38).
ª 2017 European Sleep Research Society
Branched-chain amino acid levels in OSA 5
severe sleep apnea, we found that the treatment with CPAP
for 12 weeks caused similar changes in circulating BCAA
concentrations to CT. However, higher isoleucine and valine
concentrations were found in patients with IGT and a
differential metabolic response of CPAP and CT was
detected between the relationships of BCAAs and glucose
homeostasis. Our findings include several important obser-
vations.
First, isoleucine levels were associated with HbA1c and
time spent with SpO2 <90%. Obesity-related increases in
BCAA levels are associated with dysregulation of BCAA
metabolism (Perng et al., 2014). The BCAA catabolic
enzymes are distributed widely in body tissues, and tissue-
specific alterations in BCAA metabolism could contribute to
elevated plasma BCAAs (Herman et al., 2010; Newgard,
2012; She et al., 2007). Altered systemic BCAA levels have
been found to be associated with several parameters for
glucose homeostasis, such as HOMA-IR, HbA1c and FPG
(Knebel et al., 2016; McCormack et al., 2013; Palmer et al.,
2015; Wang et al., 2011). Our results suggest that in subjects
with morbid obesity and severe sleep apnea, both obesity
and OSA may be relevant in these associations.
Secondly, a significant decrease in circulating BCAA
(leucine) levels was observed in response to dietary or
CPAP intervention. BCAAs have showed strong positive
associations with type 2 diabetes mellitus risk up to 12 years
before onset, and have also been linked to risk of cardio-
vascular disease. Conversely, several studies have sug-
gested that BCAA values could represent a biomarker of a
metabolic dysregulation with the causal metabolites yet to be
identified, and facilitate pre-emptive treatments (Ferguson
and Wang, 2016), and there is evidence that changes in
BCAA levels may correlate with the efficacy of interventions
for affecting improvement in metabolic control (Huffman
et al., 2011; Kamaura et al., 2010; Laferrere et al., 2011;
Magkos et al., 2016; Shah et al., 2012; Wang et al., 2011). In
this study, we hypothesized that changes in BCAA metabo-
lism could mediate in the improvement in insulin sensitivity
and glucose tolerance after CPAP treatment in OSA patients.
We found that both treatments caused the same decrease in
plasma leucine levels. These data do not support the
hypothesis that CPAP has independent effects on BCAA
Table 2 Effect of continuous positive airway pressure (CPAP) and conservative treatment on anthropometric, clinical, glucose and branched-
chain amino acids (BCAA) variables
CPAP group
n = 42
Conservative treatment group
n = 38
Intergroup
differences (95% CI)Baseline 12 weeks Change Baseline 12 weeks Change
BMI (kg m2) 45.7  5.0 44.7  5.0 0.96  2.6 49.3  6.6 48.3  7 0.99  2.0 0.009 (1.04 to 1.03)
Waist
circumference
(cm)
130 (120–137) 129 (119–137) 2.1  6.8 134 (126–147) 133 (121–141) 3.3  10.8 1.2 (5.18 to 2.18)
Fasting glucose
(mmol L1)
5.80  0.70 5.60  0.67 0.13  0.57 5.7  0.8 5.9  2.3 0.205  2.03 0.33 (0.10 to 0.40)
Glycosylated
haemoglobin (%)
5.8 (5.5–6.1) 5.8 (5.5–6.1) 0.035  0.2 5.7 (5.5–5.9) 5.6 (5.4–6.0) 0.075  0.6 0.04 (0.23 to 0.15)
HOMA-IR† 6.8 (4.4–8.7) 6.5 (5.2–9.3) 0.32  4.4 6.4 (5.2–11.0) 6.7 (5.1–9.3) 0.044  3.7 0.27 (1.55 to 2.1)
2 h-PG
(mmol L1)†
6.7 (5.3–8.9) 6.2 (5.1–8.5) 0.5  1.5 6.4 (5.0–7.0) 6.7 (5.7–7.9) 0.33  1.9 0.85 (1.69 to 0.01)*
Leucine (lmol L1) 136  20 122  27 14 (23 to 5)** 140  25 112  30 26 (36 to 2)** 20 (26 to 14)
Isoleucine
(lmol L1)
74  12 72  15 2 (0 to 10) 75  16 74  16 1 (3 to 6) 3 (0.6 to 6)
Valine (lmol L1) 273  37 281  38 8 (7 to 23) 276  44 278  51 2 (9 to 12) 5 (4 to 14)
BMI, body mass index; CI, confidence interval; HOMA-IR, homeostasis model assessment–insulin resistance.
*P < 0.05.
**P < 0.005.
†2 h-PG (n = 35, n = 34), HOMA-IR (n = 40, n = 38).
Table 3 Correlation of branched-chain amino acids (BCAA)
concentrations with anthropometric, sleep and glucose
metabolism variables at baseline
Valine Isoleucine Leucine
BMI 0.008 0.033 0.001
WC 0.075 0.103 0.186
Epworth scale 0.082 0.203 0.001
AHI 0.160 0.115 0.012
Time spent <90% of TST 0.216 0.244* 0.135
FG 0.153 0.141 0.138
2 h-PG 0.121 0.173 0.007
HbA1c 0.155 0.287* 0.097
HOMA index 0.010 0.075 0.042
AHI, apnea–hypopnea index; BMI, body mass index; TST, total
sleep time; HOMA, homeostasis model assessment; HbA1c,
glycosylated haemoglobin.
*P < 0.05.
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metabolism. However, the relationships among surrogate
measures of glucose homeostasis and BCAAs (leucine,
isoleucine) differ according to treatment, and our data
demonstrate that baseline BCAA levels are correlated with
HbA1c and FPG values after treatment only in the CT group.
In addition, in response to conservative treatment, changes in
levels of leucine and isoleucine were related negatively to
changes in FPG and HBA1c values, suggesting that BCAA
levels at baseline may be potential contributors in predicting
change in FPG and HBA1c after a dietary weight loss
intervention and that the greater the BCAA levels at baseline,
the smaller the improvement in HbA1c with weight loss. A
possible explanation for our findings is that CPAP treatment
does not appear to affect changes in BCAA concentrations
directly, but it may nevertheless counteract the deleterious
associations between baseline BCAAs and measures of
diabetes risk, potentially via downstream pathways or alter-
native mechanisms.
Thirdly, we detected that patients with IGT had higher levels
of isoleucine and valine compared to patients with normal
glucose tolerance. Similar changes after treatment were
found between patients with IGT and NGT. Therefore, we
observed that in patients with IGT, baseline BCAA levels
(isoleucine, leucine) correlated positively with after-treatment
HbA1c values and negatively with HbA1c change after
treatment only in the CT group, suggesting again that the
greater the BCAA levels at baseline, the smaller the improve-
ment in HbA1c after a dietary therapy. We did not find any
relationships between baseline BCAAs and after treatment
glycaemic measures in the CPAP group. Taken together,
these observations suggest a role for circulating BCAAs in
mediating glucose tolerance in CPAP treatment compared to
conservative treatment. The improvement in glucose toler-
ance observed after 12 weeks of CPAP therapy may reflect
the reduction in muscle insulin resistance, and in this context
one hypothesis is that BCAA homeostasis may be an
intermediate step in modulating muscle insulin resistance
with differential functional consequences. However, whether
BCAAs are involved in a development of insulin resistance in
a functional manner or represent a biomarker of a metabolic
dysregulated status is yet to be elucidated (Newbern et al.,
2014; Patti et al., 1998; Tai et al., 2010; Wurtz et al., 2013).
Our knowledge concerning the biological processes affected
by BCAA metabolism and how both systemic and local BCAA
metabolism is impaired under pathological stressors such as
sleep apnea is largely unknown, and therefore more research
is needed to understand these complex biological mecha-
nisms. Our results suggest the potential utility for BCAAs in
understanding specific metabolic responses during CPAP
treatment, diet-induced weight loss or lifestyle modification in
patients with OSA.
Several limitations of the study should be noted. First,
concerning the short period of treatment of 12 weeks, a
large-scale long-term study is required to confirm our
observations. Secondly, we think that the lack of differences
between BMI and insulin resistance (HOMA-IR) might be due
to the fact that the patients included were extremely obese
and highly insulin-resistant, and we cannot draw conclusions
about the generalizability of our results.
Table 4 Cross-sectional associations for changes in branched-chain amino acids (BCAA) concentrations and changes in anthropometric
and glucose metabolism variables
Change
CPAP group
n = 42
Conservative treatment group
n = 38
Leucine
change
Isoleucine
change
Valine
change
Leucine
change
Isoleucine
change
Valine
change
Fasting glucose change 0.114 0.112 0.113 0.323* 0.173 0.048
2 h-PG change 0.217 0.145 0.105 0.036 0.122 0.015
Glycosylated haemoglobin change 0.163 0.099 0.106 0.136 0.409* 0.121
HOMA-IR change 0.073 0.136 0.178 0.226 0.005 0.215
BMI change 0.035 0.109 0.241 0 to 147 0.185 0.025
BMI, body mass index; CPAP, continuous positive airway pressure; HOMA-IR, homeostasis model assessment–insulin resistance.
*P < 0.05.
Figure 2. Branched-chain amino acid (BCAA) concentrations in
patients with normal glucose tolerance (NGT) and impaired glucose
tolerance (IGT).
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CONCLUSIONS
In summary, we found that CPAP and dietary intervention
caused similar changes in circulating BCAA concentrations.
A differential metabolic response of CPAP and conservative
treatment was detected between the relationships of levels of
BCAAs and measures of glucose homeostasis. Additional
studies are needed to determine the interplay between
branched-chain amino acids and glucose metabolism and
their potential role in the development of insulin resistance
and metabolic disorders in patients with sleep apnea.
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